New Data on QoL With Apalutamide in Prostate Cancer New Data on QoL With Apalutamide in Prostate Cancer

Delayed deterioration of quality of life was consistent with longer time to symptomatic progression, according to new data from the SPARTAN trial.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news